1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > MarketVIEW: Respiratory Syncytial virus vaccines

MarketVIEW: Respiratory Syncytial virus vaccines

  • May 2012
  • -
  • VacZine Analytics Group Of Assay Advantage Ltd
  • -
  • 60 pages

Respiratory syncytial virus (RSV) is a leading cause of infant/childhood lower respiratory tract infection and hospitalization. Elderly adults and those with underlying co-morbidities such as chronic obstructive pulmonary disease (COPD) or suffering with malignancies are also at increased risk of RSV infection related complications. RSV is estimated to be responsible for ~9,000 deaths per year (US).

An RSV prophylactic vaccine would ideally to reduce the incidence of severe RSV lower respiratory tract infections in "at risk" groups. Currently a number of approaches are being pursued including live-attenuated viruses and/or recombinant proteins, the most advanced of which is AstraZeneca/Medimmune's MEDI-534 and MEDI-559. US biotech Novavax have also completed a Phase I trial with VLP recombinant RSV-F fusion protein. 

This MarketVIEW is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of new RSV vaccines across global markets to 2030. The model contains value ($ m) and volume (mio doses) predictions for infants (<1yrs) and various adult target groups. Differing RSV vaccine profiles (infant + elderly) and related issues such as differential pricing are also discussed with regard to LO/BASE/HI market uptake scenarios. 

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL 

Table Of Contents

MarketVIEW: Respiratory Syncytial virus vaccines
Executive summary
Commercial model - key outputs
Total predicted demand (doses 000s), all scenarios
Total global available market ($000s), all scenarios
Total global available market ($000s), infant
Total global available market ($000s), adult “at risk”
Total global available market ($000s), adult “universal”
The role of a RSV vaccine
Vaccine target populations: overview
Vaccine target populations: scenario definitions
RSV vaccine: infant target product profile
RSV vaccine: adult target product profile
Markets included in the model
Commercial model assumptions: infant scenario
Commercial model assumptions: adult scenarios
Model forecast comparisons: March 2010 v current model (May 2012)
Pricing methodology: infant and adults
Competitor landscape overview
MedImmune: MEDI-534 and MEDI-559 vaccines
Novavax: VLP RSV-F vaccine
Novavax: Phase I data
Preclinical vaccines
Vaccine pipeline summary
Estimated launch dates
Opportunities for new treatments
Review of latest epidemiology
Epidemiology: infants
Epidemiology: adults
Epidemiology: hospitalizations
Methodology: target populations
Methodology: coverage
Model forecast comparisons: Novavax/LEK analysis
Bibliography
About VacZine Analytics
Disclaimer
PAGES: 60 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents - Vaccine demand model (MS Excel-based)
Title sheet
Scenarion definitions
GRAND SUMMARY CHARTS
CHARTS VALUE
CHARTS VOLUME
CHARTS VOLUME - HIGH
VALUE SUMMARY - universal
VALUE SUMMARY - “at risk”
VALUE SUMMARY - infants
VOLUME SUMMARY - universal
VOLUME SUMMARY - “at risk”
VOLUME SUMMARY - infants
Country volume/population sheets
US
Canada
UK
Germany
France
Spain
Italy
Other EU
Japan
Brazil
India
China
Mexico
Country total populations - forecast to 2030 (Births, >18 yrs, >65 yrs)
Source material
US RSV
Japan RSV
US Pneumonia
Asthma/COPD epidemiology
CHF epidemiology
Cancer EPI
Pricing (infant)
Coverage (COPD and HF)
Back page
About VacZine Analytics
Disclaimer
WORKSHEETS: ~65

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Analysis of the Global Vaccines Delivery Market : Innovative Technologies and Future Trends for Stakeholders

Analysis of the Global Vaccines Delivery Market : Innovative Technologies and Future Trends for Stakeholders

  • $ 6 500
  • Industry report
  • March 2015
  • by Frost & Sullivan

Methodology The analysis in this research service is based on the following: •Information collected through discussions with market participants. •Information from secondary pharmaceutical companies, ...

Meningococcal Vaccines Market (Polysaccharide, Conjugate, Combination and Men B Vaccines, along with Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022

Meningococcal Vaccines Market (Polysaccharide, Conjugate, Combination and Men B Vaccines, along with Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022

  • $ 4 795
  • Industry report
  • May 2015
  • by Transparency Market Research

Meningococcal disease, especially meningococcal meningitis, is one of the most catastrophic infections among individuals or communities. Several meningococcal serogroups have been identified till date, ...

Veterinary / Animal Vaccines Market by Product, Diseases  & Technology  - Global Forecast to 2020

Veterinary / Animal Vaccines Market by Product, Diseases & Technology - Global Forecast to 2020

  • $ 4 650
  • Industry report
  • June 2015
  • by MarketsandMarkets

The report segments the veterinary vaccines market on the basis of products, diseases, technologies, and regions. On basis of products, the veterinary vaccines market is categorized into companion animal ...

Vaccines Markets In China

June 2015 $ 4 000

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.